Recombinant Rat Somatostatin receptor type 5 (Sstr5)

What is Somatostatin Receptor Type 5 (SSTR5) and what is its function in rat models?

SSTR5 is a G protein-coupled receptor that functions as a receptor for somatostatin-28. Its activity is mediated by G proteins, particularly Gαi, which inhibit adenylyl cyclase . In rat models, SSTR5 plays a crucial role in various physiological processes, including hormone regulation and cell growth inhibition. It forms heterodimers with SSTR2, which increases the cell growth inhibition activity of SSTR2 . SSTR5 is primarily located in the cell membrane and is involved in mediating the inhibitory effects of somatostatin on various cellular functions.

In rat embryonic development, SSTR5 protein has been observed as early as embryonal day 10, though interestingly, some studies have not detected SSTR5 mRNA expression in whole rat embryos while still detecting the protein . This suggests complex post-transcriptional regulatory mechanisms that warrant further investigation.

How does SSTR5 differ from other somatostatin receptor subtypes?

Among the five somatostatin receptor subtypes (SSTR1-5), SSTR5 shows distinct characteristics:

• Binding Preferences: SSTR5 has higher affinity for somatostatin-28 compared to somatostatin-14, unlike other subtypes.

• Structural Uniqueness: Recent cryo-EM structures reveal that SSTR5 has distinct conformational changes upon binding to cyclic peptide agonists like cortistatin-17 (CST17) and octreotide .

• Developmental Expression: While other receptor subtypes like SSTR1-2 and SSTR4 show peak mRNA expression at day 14 in rat embryonic development, and SSTR3 appears at day 15, the expression profile of SSTR5 differs significantly .

• Functional Role: SSTR5 specifically mediates the inhibition of peptide YY secretion in response to somatostatin-28 stimulation, a function not shared by other subtypes .

• Co-localization Patterns: In pancreatic islets, SSTR5 primarily co-localizes with glucagon and pancreatic polypeptide-producing cells, while other subtypes show different cellular associations. For example, SSTR2 is present in all islet endocrine cells except β-cells, and SSTR3-4 co-localize with insulin and pancreatic polypeptide .

What is the expression profile of SSTR5 during rat embryonic development?

The developmental expression of SSTR5 in rats follows a complex pattern:

• Protein Expression: SSTR5 protein has been detected as early as embryonal day 10 .

• Tissue Distribution: From embryonal day 11 to birth, SSTR5 protein presence increases progressively in major structures such as skin and cartilage, while remaining relatively stable in tissues like heart and liver .

• Pancreatic Expression: In the fetal pancreas, SSTR5 protein shows specific co-localization with glucagon and pancreatic polypeptide-producing cells .

• mRNA Expression Peculiarity: Interestingly, some studies have reported no detectable SSTR5 mRNA expression in whole rat embryos despite observing the protein . This discrepancy suggests possible post-transcriptional regulatory mechanisms or technical limitations in mRNA detection methods.

What is the structural basis for SSTR5 activation by agonists like cortistatin-17 and octreotide?

Recent cryo-EM studies have revealed the molecular mechanisms of SSTR5 activation:

• High-Resolution Structures: Cryo-EM structures of SSTR5-Gi complexes bound to cortistatin-17 (CST17) and octreotide have been determined at 2.7 Å and 2.9 Å resolutions, respectively .

• Hydrophobic Lock Mechanism: Both CST17 and octreotide trigger the rearrangement of a "hydrophobic lock" consisting of residues from transmembrane helices TM3 and TM6. This rearrangement causes an outward movement of TM6, enabling Gαi protein engagement and receptor activation .

• Distinct Binding Modes: Despite sharing a conserved F(L/D)WKT motif, CST17 and octreotide exhibit different interaction modes with SSTR5 due to variations in disulfide bond positions .

• Key Structural Differences:

  • CST17 forms conserved polar contacts similar to those observed in somatostatin-14 binding to SSTR2

  • Octreotide binding involves a crucial intrareceptor polar network comprising Q99^2.63, T185^ECL2, and N187^45.51 that is not observed with CST17

• Role of Extracellular Loops: The extracellular loops of SSTR5 respond differently to CST17 and octreotide, contributing to ligand selectivity. Mutations like N187^45.51T or T185^ECL2W in SSTR5 (which mimic SSTR2's ECL2 residues) significantly enhance octreotide's efficacy in activating SSTR5 .

How do SSTR5 activation mechanisms differ from classic Class A GPCR activation paradigms?

SSTR5 shows both conserved and distinctive features in its activation mechanism compared to other Class A GPCRs:

• Conserved Features: Like other class A GPCRs, activated SSTR5 exhibits:

  • Outward movement of the cytoplasmic tail of TM6

  • Inward movement of TM7

• Distinctive Features: SSTR5 shows subtle deviations from established Class A GPCR activation mechanisms:

  • Unique conformational changes in the "hydrophobic lock" region

  • Specific involvement of extracellular loops in ligand recognition

  • Distinct patterns of stabilizing interactions during activation

• Ligand-Specific Activation: Different agonists (CST17 vs. octreotide) induce subtle conformational differences (RMSD values of 1.43 Å for the receptor and 1.50 Å across entire complexes), highlighting the plasticity in SSTR5 activation mechanisms .

What are the molecular determinants of agonist selectivity between SSTR5 and other somatostatin receptor subtypes?

Several key molecular features determine agonist selectivity for SSTR5:

• Extracellular Loop Configuration: The extracellular loops of SSTR5 play a crucial role in specific recognition of different agonists. For example, ECL2 is particularly important for octreotide selectivity .

• Polar Interaction Networks: A polar network formed by Q99^2.63, T185^ECL2, and N187^45.51 appears to influence octreotide binding and may actually hinder activation of SSTR5 by octreotide relative to other receptor subtypes .

• Key Residue Differences: Mutations that transform SSTR5 residues to match those in SSTR2 (such as N187^45.51T or T185^ECL2W) enhance octreotide efficacy, highlighting the importance of these residues in determining subtype selectivity .

• Ligand Structure Variations: The positioning of disulfide bonds within peptide ligands creates structural variations that lead to different interaction modes with the receptor subtypes. This is evident in the distinct binding conformations of CST17 and octreotide within SSTR5 .

What are the optimal techniques for measuring SSTR5 expression in rat tissue samples?

Several complementary methods are recommended for comprehensive assessment of SSTR5 expression:

• RT-PCR for mRNA Detection:

  • Calculate results by comparing the difference between crossing point (cp) values of the amplified sample and housekeeping mRNA using the formula 2^-Δ(cpSSTR5-cpTBP) .

• ELISA for Protein Quantification:

  • Commercially available Rat SSTR5 ELISA kits offer:

    • Detection range: 7.8-500 pg/mL

    • Sensitivity: 3.94 pg/mL

    • Appropriate for serum, plasma, tissue homogenates, and cell culture supernatants

• Immunohistochemistry for Localization:

  • Particularly useful for determining co-localization with other cellular markers

  • Has successfully identified SSTR5 in embryonic tissues as early as day 10

• Single-Point Mutation Analysis:

  • Can be used to assess functional significance of specific residues

  • Example mutations like Q99^2.63A and N187^45.51A have demonstrated varying effects on receptor activation

How should researchers design experiments to investigate SSTR5-mediated signaling pathways?

A comprehensive experimental approach should include:

• Receptor Activation Studies:

  • Measure inhibition of adenylyl cyclase activity as SSTR5 activation inhibits this enzyme through Gαi proteins

  • Compare responses to different agonists (somatostatin-28, CST17, octreotide) to assess ligand-specific effects

• Protein-Protein Interaction Studies:

  • Investigate SSTR5 heterodimerization with SSTR2, which increases cell growth inhibition activity

  • Employ co-immunoprecipitation or proximity ligation assays to confirm interactions

• Mutagenesis Approaches:

  • Target key residues identified in structural studies:

    • Hydrophobic lock residues in TM3 and TM6

    • Extracellular loop residues (particularly N187^45.51 and T185^ECL2)

    • Residues involved in G-protein coupling

• Developmental Expression Studies:

  • Combine mRNA and protein detection methods due to potential discrepancies

  • Include multiple developmental timepoints (examples from published work include embryonal days 10, 11, 12, 14, 15, 17, 19, 21, and birth)

• Controls and Validation:

  • Include appropriate pharmacological controls (antagonists like pasireotide)

  • Validate findings with multiple methodologies to address potential technique-specific limitations

What considerations are important when using recombinant rat SSTR5 for structural and functional studies?

When working with recombinant rat SSTR5:

• Expression System Selection:

  • Insect cell expression systems have been successfully used for structural studies

  • Co-expression with heterotrimeric G proteins and stabilizing antibody fragments (like scFv16) enhances stability

• Receptor Stabilization:

  • Consider introducing stabilizing mutations (e.g., L6.40 mutation used in structural studies maintained normal receptor function)

  • Assess effects of any modifications through functional assays

• Ligand Selection:

  • Different ligands induce distinct conformational states

  • Cyclic peptides like CST17 and octreotide have been successfully used in structural studies

• Functional Validation:

  • Verify that recombinant SSTR5 maintains appropriate:

    • Ligand binding affinity

    • G protein coupling

    • Signaling properties

    • Response to known agonists/antagonists

• Structural Analysis Considerations:

  • Be aware of potential limitations in modeling certain regions (N and C termini showed limited density in cryo-EM structures)

  • Consider the impact of fusion partners or tags on receptor function

How can researchers effectively analyze contradictory data in SSTR5 developmental expression studies?

When faced with contradictory data such as the discrepancy between SSTR5 mRNA and protein detection in embryonic studies:

• Technical Validation:

  • Employ multiple primer sets for RT-PCR to rule out technical limitations

  • Verify antibody specificity through knockout controls or competing peptides

  • Use multiple detection methods (in situ hybridization, RT-PCR, immunohistochemistry, Western blot)

• Tissue-Specific Analysis:

  • Whole embryo preparations may dilute tissue-specific signals

  • Consider microdissection to isolate specific tissues of interest

  • Perform single-cell RNA sequencing to detect cell-specific expression patterns

• Developmental Timeline Considerations:

  • Increase sampling frequency during critical developmental windows

  • Consider potential transient expression patterns that might be missed with limited timepoints

• Post-Transcriptional Regulation Assessment:

  • Investigate microRNA regulation of SSTR5 mRNA

  • Assess mRNA stability through actinomycin D chase experiments

  • Examine potential alternative splicing events

• Data Integration Framework:

  • Create a comprehensive table comparing results across methodologies and developmental timepoints

  • Weight evidence based on methodological strengths and limitations

  • Consider biological explanations for apparent contradictions

What are promising approaches for developing SSTR5-selective therapeutic agents?

Based on recent structural and functional insights:

• Structure-Guided Design:

  • Leverage the high-resolution cryo-EM structures of SSTR5 bound to CST17 and octreotide

  • Focus on exploiting the "hydrophobic lock" mechanism for selective activation

  • Design peptides or small molecules that specifically engage the unique features of the SSTR5 binding pocket

• Extracellular Loop Targeting:

  • Develop compounds that specifically interact with the extracellular loops of SSTR5, which play a crucial role in ligand selectivity

  • Consider the polar network formed by Q99^2.63, T185^ECL2, and N187^45.51 as a potential target

• Biased Agonism Exploration:

  • Design ligands that selectively activate specific downstream pathways

  • Study the distinct conformational states induced by different ligands to understand the structural basis of biased signaling

• Heterodimer-Specific Approaches:

  • Develop compounds that specifically target SSTR5-SSTR2 heterodimers, which show enhanced growth inhibition activity

  • Consider bivalent ligands that can simultaneously engage both receptors in the heterodimer

How can advanced genetic models improve our understanding of SSTR5 function in physiological and pathological conditions?

Several genetic approaches offer promising avenues for SSTR5 research:

• Conditional Knockout Models:

  • Generate tissue-specific and inducible SSTR5 knockout rat models

  • Study the temporal and spatial requirements for SSTR5 in development and disease

  • Assess compensatory mechanisms involving other somatostatin receptor subtypes

• Knock-in Models with Reporter Tags:

  • Create knock-in models expressing SSTR5 fused to fluorescent proteins or epitope tags

  • Enable real-time visualization of receptor trafficking and localization

  • Facilitate isolation of SSTR5-expressing cells for transcriptomic and proteomic analysis

• CRISPR-Based Approaches:

  • Introduce specific mutations identified in structural studies to validate their functional significance in vivo

  • Create models expressing humanized SSTR5 for better translational relevance

  • Generate models with mutations that affect heterodimer formation to study SSTR5-SSTR2 interactions

• Disease Models:

  • Introduce SSTR5 mutations or expression changes associated with human diseases

  • Study the role of SSTR5 in models of neuroendocrine tumors, pituitary disorders, and pancreatic dysfunction

  • Evaluate potential therapeutic interventions targeting SSTR5